Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Scancell Holdings stock

SCLP.L
GB00B63D3314
A1JZ3D

Price

0.15
Today +/-
-0.01
Today %
-5.70 %
P

Scancell Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Scancell Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Scancell Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Scancell Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Scancell Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Scancell Holdings Stock Price History

DateScancell Holdings Price
11/18/20240.15 undefined
11/15/20240.16 undefined
11/14/20240.15 undefined
11/13/20240.14 undefined
11/12/20240.14 undefined
11/11/20240.14 undefined
11/8/20240.14 undefined
11/7/20240.13 undefined
11/6/20240.13 undefined
11/5/20240.13 undefined
11/4/20240.13 undefined
11/1/20240.13 undefined
10/31/20240.13 undefined
10/30/20240.13 undefined
10/29/20240.14 undefined
10/28/20240.15 undefined
10/25/20240.15 undefined
10/24/20240.15 undefined
10/23/20240.15 undefined
10/22/20240.15 undefined
10/21/20240.14 undefined

Scancell Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Scancell Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Scancell Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Scancell Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Scancell Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Scancell Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Scancell Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Scancell Holdings’s growth potential.

Scancell Holdings Revenue, EBIT and net profit per share

DateScancell Holdings RevenueScancell Holdings EBITScancell Holdings Net Income
2026e0 undefined-18.25 M undefined-14.37 M undefined
2025e1.65 M undefined-13.13 M undefined-13.21 M undefined
2024e0 undefined-15.79 M undefined-17.8 M undefined
20235.27 M undefined-11.92 M undefined-11.94 M undefined
20220 undefined-14.26 M undefined-4.57 M undefined
20210 undefined-9.75 M undefined-15.48 M undefined
20200 undefined-6.78 M undefined-5.51 M undefined
20190 undefined-6.73 M undefined-5.63 M undefined
20180 undefined-4.94 M undefined-4.19 M undefined
20170 undefined-4.55 M undefined-3.54 M undefined
20160 undefined-3.04 M undefined-2.58 M undefined
20150 undefined-2.96 M undefined-2.41 M undefined
20140 undefined-2.5 M undefined-2.22 M undefined
20130 undefined-2.18 M undefined-1.9 M undefined
20120 undefined-1.96 M undefined560,000 undefined
20110 undefined-1.73 M undefined-1.65 M undefined
20100 undefined-1.81 M undefined-1.74 M undefined
20090 undefined-890,000 undefined-790,000 undefined
20080 undefined-510,000 undefined-410,000 undefined
20072.18 M undefined1.01 M undefined890,000 undefined
200630,000 undefined-730,000 undefined-640,000 undefined
200510,000 undefined-1.21 M undefined-1.05 M undefined

Scancell Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0020000000000000005010
----------------------
--200.00---------------80.00-400.00-
0000000000000000004000
-10000-1-10-1-2-2-2-3-4-5-5-15-4-11-17-13-14
---------100.00--50.0033.3325.00-200.00-73.33175.0054.55-23.537.69
15.8615.8615.2674.687.77113.04167.8196.08204.81222.81231.3233.22268.06319.56395.42466.19678.89815.54816.37000
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Scancell Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Scancell Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (k)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
                                     
0.740.21.5111.522.831.113.531.495.573.066.532.6710.34.563.5841.1128.7319.92
01000400000000001006800000
0.160.110.020.050000000000.741.830000
0000000000000000000
00000105080508040204000310720450410
0.90.321.531.051.922.841.163.611.545.653.16.552.7111.147.073.8941.8329.1820.33
0.320.250.110.090.080.130.10.110.130.120.090.060.090.080.060.20.982.742.25
0000000000000000000
00000000000000002.843.180
101000000000000000000
00003.423.423.423.423.423.423.423.423.423.423.423.423.423.423.42
0000000000000000000
0.330.260.110.093.53.553.523.533.553.543.513.483.513.53.483.627.249.345.67
1.230.581.641.145.426.394.687.145.099.196.6110.036.2214.6410.557.5149.0738.5226
                                     
20202080100160160190190220220260260370390470820820820
4.684.684.6805.918.328.379.99.916.0416.0421.7921.7933.3734.6438.3965.0265.0265.18
-3,520-4,160-3,270970-760-2,430-3,890-3,130-5,010-7,180-9,510-12,050-15,550-19,810-25,690-31,210-46,350-47,720-72,230
00000000000000000.711.40
0000000000000000000
1.180.541.431.055.256.054.646.965.089.086.75106.513.939.347.6520.1919.52-6.23
0.030.020.050.030.170.360.080.220.180.230.370.320.270.71.210.40.820.571.31
0.030.020.01000000.010.010.010.050.03000.651.271.571.66
00150500904070130290220210220000000
0000000000000000000
00000000000000050210320310
0.060.040.210.080.170.450.120.290.320.530.60.580.520.71.211.12.32.463.28
0000000000000000.0815.257.8619.23
0000000000000000000
000000000000000012.0310.114
0000000000000000.0827.2817.9633.23
0.060.040.210.080.170.450.120.290.320.530.60.580.520.71.211.1829.5820.4236.51
1.240.581.641.135.426.54.767.255.49.617.3510.587.0214.6310.558.8349.7739.9430.28
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Scancell Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Scancell Holdings's financial health and stability.

Assets

Scancell Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Scancell Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Scancell Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Scancell Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (k)DEPRECIATION (M)DEFERRED TAXES (k)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (k)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
-1,00001,00000-1,000-1,0000-2,000-2,000-2,000-3,000-4,000-4,000-6,000-6,000-16,000-3,000-14,000
0000000000000000000
000000000000000001,0000
0000000000000001012
00000000000000008-83
0000000000000000000
000000000000000-10-1-1
-1,00001,0000-1,000-1,000-1,0000-2,000-2,000-2,000-2,000-3,000-4,000-7,000-4,000-7,000-10,000-8,000
00000000000000000-10
00000000000000000-10
0000000000000000000
0000000000000000000
00000000000000002300
100002010606012132400
100012010605011134600
00001,00000000000000-1,00000
0000000000000000000
001011-12-24-23-37-5037-12-8
-1.16-0.671.18-0.53-1.12-1.57-1.780.82-2.07-2.11-2.64-2.33-3.91-4.07-7.03-4.8-8.54-11.46-8.34
0000000000000000000

Scancell Holdings stock margins

The Scancell Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Scancell Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Scancell Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Scancell Holdings's sales revenue. A higher gross margin percentage indicates that the Scancell Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Scancell Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Scancell Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Scancell Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Scancell Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Scancell Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Scancell Holdings Margin History

Scancell Holdings Gross marginScancell Holdings Profit marginScancell Holdings EBIT marginScancell Holdings Profit margin
2026e90.13 %0 %0 %
2025e90.13 %-795.51 %-800.62 %
2024e90.13 %0 %0 %
202390.13 %-226.19 %-226.57 %
202290.13 %0 %0 %
202190.13 %0 %0 %
202090.13 %0 %0 %
201990.13 %0 %0 %
201890.13 %0 %0 %
201790.13 %0 %0 %
201690.13 %0 %0 %
201590.13 %0 %0 %
201490.13 %0 %0 %
201390.13 %0 %0 %
201290.13 %0 %0 %
201190.13 %0 %0 %
201090.13 %0 %0 %
200990.13 %0 %0 %
200890.13 %0 %0 %
200790.13 %46.33 %40.83 %
200690.13 %-2,433.33 %-2,133.33 %
200590.13 %-12,100 %-10,500 %

Scancell Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Scancell Holdings earnings per share therefore indicates how much revenue Scancell Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Scancell Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Scancell Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Scancell Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Scancell Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Scancell Holdings Revenue, EBIT and net profit per share

DateScancell Holdings Sales per ShareScancell Holdings EBIT per shareScancell Holdings Earnings per Share
2026e0 undefined0 undefined-0.02 undefined
2025e0 undefined0 undefined-0.01 undefined
2024e0 undefined0 undefined-0.02 undefined
20230.01 undefined-0.01 undefined-0.01 undefined
20220 undefined-0.02 undefined-0.01 undefined
20210 undefined-0.01 undefined-0.02 undefined
20200 undefined-0.01 undefined-0.01 undefined
20190 undefined-0.02 undefined-0.01 undefined
20180 undefined-0.02 undefined-0.01 undefined
20170 undefined-0.02 undefined-0.01 undefined
20160 undefined-0.01 undefined-0.01 undefined
20150 undefined-0.01 undefined-0.01 undefined
20140 undefined-0.01 undefined-0.01 undefined
20130 undefined-0.01 undefined-0.01 undefined
20120 undefined-0.01 undefined0 undefined
20110 undefined-0.01 undefined-0.01 undefined
20100 undefined-0.02 undefined-0.02 undefined
20090 undefined-0.01 undefined-0.01 undefined
20080 undefined-0.01 undefined-0.01 undefined
20070.14 undefined0.07 undefined0.06 undefined
20060 undefined-0.05 undefined-0.04 undefined
20050 undefined-0.08 undefined-0.07 undefined

Scancell Holdings business model

Scancell Holdings PLC is a biotechnology company specializing in the development of immunotherapies for cancer. The company was founded in 1997 and is headquartered in Nottingham, United Kingdom. Scancell's goal is to improve the lives of patients with cancer by developing innovative therapies that selectively activate the body's immune system. Scancell's business model is based on the research, development, and commercialization of immunotherapies. The company has developed a platform technology called Modified Vaccinia Ankara (MVA), which is a widely used virus in vaccine research and development. Scancell uses this platform technology to develop vaccines that selectively activate the immune system against cancer cells. The company works closely with academic partners and other biotech companies. The company has two main divisions: Scancell Immunotherapy and Scancell Biotherapeutics. Under the Scancell Immunotherapy division, the company develops cancer vaccines. Scancell is actively working on the development of two main products: SCIB1 and Modi-1. SCIB1 is an immunotherapy based on a DNA-based vaccine that activates the immune system to attack cancer cells. This vaccine has been studied in various clinical trials and has shown promising results. SCIB1 has been tested in a Phase II study on patients with advanced melanoma and has triggered a strong immune response in most patients. The company is now working on further developing SCIB1 in clinical trials. Modi-1 is an immunotherapy based on a novel technology called Modified T-cells. These are engineered T-cells that compel the immune system to recognize and attack cancer cells. Modi-1 is still in the development phase and has not yet been tested in clinical trials. Under the Scancell Biotherapeutics division, the company develops antibodies for cancer treatment. The company focuses on developing antibodies that target specific cancer antigens. Scancell has already developed several promising antibody candidates, including AvidiMabTM, an antibody candidate against the CD98 receptor, which is overexpressed in many cancer cells. Scancell is currently listed on the London Stock Exchange and has a market capitalization of around £250 million. The company also has a strong pipeline of products in development and is actively working to realize their potential. Scancell has a strong partnership with AstraZeneca, one of the world's largest pharmaceutical companies, to support its research and development activities. In summary, Scancell is an emerging biotech company specializing in the development of immunotherapies for cancer. The company has a strong pipeline of products in development and works closely with leading scientists and academic institutions. Scancell is a promising company that offers exciting opportunities for both investors and patients. Scancell Holdings is one of the most popular companies on Eulerpool.com.

Scancell Holdings SWOT Analysis

Strengths

  • Scancell Holdings PLC has a strong portfolio of immunotherapy technologies that are designed to target and treat various forms of cancer.
  • The company's flagship drug, SCIB1, has shown promising results in clinical trials, demonstrating its potential effectiveness in treating melanoma.
  • Scancell has a diverse and experienced management team, who are knowledgeable in the field of cancer immunotherapy and have a track record of successful drug development.

Weaknesses

  • As a relatively small biotechnology company, Scancell faces financial limitations and may struggle to compete with larger pharmaceutical companies in terms of resources and funding.
  • The success of Scancell's immunotherapy technologies heavily relies on successful clinical trials and regulatory approvals, which can be a lengthy and costly process.

Opportunities

  • The growing global demand for effective cancer treatments presents a significant opportunity for Scancell to commercialize its immunotherapy technologies and secure partnerships with larger pharmaceutical companies.
  • The advancements in personalized medicine and genomic research offer potential avenues for Scancell to further develop and tailor its immunotherapy treatments to individual patients.

Threats

  • Intense competition from other biotechnology and pharmaceutical companies in the cancer immunotherapy market poses a threat to Scancell's market share and potential revenue.
  • Regulatory challenges and uncertainties surrounding the approval and reimbursement of immunotherapy treatments may delay or hinder the commercialization of Scancell's products.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Scancell Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Scancell Holdings historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Scancell Holdings shares outstanding

The number of shares was Scancell Holdings in 2023 — This indicates how many shares 816.37 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Scancell Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Scancell Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Scancell Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Scancell Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Scancell Holdings stock splits

In Scancell Holdings's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Scancell Holdings.

Scancell Holdings shareholders

%
Name
Stocks
Change
Date
28.89597 % Redmile Group, LLC268,616,93608/31/2024
12.66448 % Vulpes Investment Management Private Limited117,729,029-2,181,8188/31/2024
3.31667 % Calculus Capital Limited30,831,721-3,207,2888/31/2024
0.91797 % Platinum Asset Management8,533,47207/31/2024
0.81505 % Wood (Sir Martin Francis)7,576,71509/1/2024
0.49484 % British Business Aspire Holdco Ltd.4,600,00009/1/2024
0.34258 % Ichor Medical Systems, Inc.3,184,630102/13/2023
0.28163 % Wiseman (Anthony Patrick James)2,618,03009/1/2024
0.25613 % Wild (Sarah Gordon)2,380,95209/1/2024
0.24390 % Isu Chemical Co Ltd2,267,28009/1/2024
1
2
3
4

Scancell Holdings Executives and Management Board

Prof. Lindy Durrant
Scancell Holdings Chief Executive Officer, Chief Scientific Officer, Executive Director (since 2021)
Compensation 369,125
Ms. Susan Clement-Davies
Scancell Holdings Non-Executive Independent Director
Compensation 55,000
Dr. Ursula Ney(70)
Scancell Holdings Non-Executive Independent Director
Compensation 40,000
Mr. Jean-Michel Cossery(63)
Scancell Holdings Non-Executive Chairman of the Board
Compensation 25,000
Mr. Sath Nirmalananthan
Scancell Holdings Chief Financial Officer
1
2

Most common questions regarding Scancell Holdings

What values and corporate philosophy does Scancell Holdings represent?

Scancell Holdings PLC represents a strong commitment to innovative cancer immunotherapies. The company's corporate philosophy revolves around developing novel, targeted immunotherapies to treat and prevent cancer. Scancell Holdings PLC focuses on leveraging its expertise in the field of ImmunoBody® and Moditope® platforms to create breakthrough treatments that harness the power of the immune system. With a dedicated team of scientists and researchers, Scancell is driven by a vision to improve patients' lives through effective and personalized cancer treatments. This UK-based biotechnology company is at the forefront of advancing immunotherapeutic solutions and is dedicated to making a positive impact in the fight against cancer.

In which countries and regions is Scancell Holdings primarily present?

Scancell Holdings PLC primarily operates in the United Kingdom.

What significant milestones has the company Scancell Holdings achieved?

Some significant milestones achieved by Scancell Holdings PLC include the successful development of their innovative ImmunoBody® and Moditope® platforms for cancer immunotherapy. The company has made notable progress in advancing its lead product, SCIB1, through clinical trials, demonstrating promising results in the treatment of melanoma patients. In addition, Scancell has achieved important collaborations and partnerships with renowned organizations, such as Cancer Research UK and the University of Nottingham, further validating their technologies. These achievements highlight Scancell Holdings PLC's dedication to advancing cancer treatment options and building strong industry alliances.

What is the history and background of the company Scancell Holdings?

Scancell Holdings PLC is a renowned biotechnology company specializing in the development of novel immunotherapies for the treatment of cancer. Established in 1997, Scancell has pushed the boundaries of cancer research and developed innovative platforms such as ImmunoBody® and Moditope®. The company's cutting-edge technology stimulates the body's immune system to target and eliminate cancer cells selectively. Scancell's dedication to advancing cancer treatment has earned them recognition worldwide. With an experienced team of scientists and a strong commitment to innovation, Scancell Holdings PLC continues to be at the forefront of immunotherapy development, offering hope for improved cancer therapies in the future.

Who are the main competitors of Scancell Holdings in the market?

The main competitors of Scancell Holdings PLC in the market include pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, and Merck & Co. These companies are also involved in developing innovative therapies and treatments for various diseases. As a leading player in the biotechnology sector, Scancell Holdings PLC faces competition in terms of research capabilities, product development, and market presence. However, Scancell Holdings PLC distinguishes itself with its unique immuno-oncology platform and promising pipeline. Its dedication to advancing immunotherapies places the company in a competitive position within the market.

In which industries is Scancell Holdings primarily active?

Scancell Holdings PLC is primarily active in the biopharmaceutical industry.

What is the business model of Scancell Holdings?

The business model of Scancell Holdings PLC focuses on the development and commercialization of novel immunotherapies to treat cancer. The company utilizes its ImmunoBody® and Moditope® platforms to create innovative and effective treatment options. Scancell aims to leverage its expertise in immunology and cancer biology to develop therapies that activate the patient's immune system to specifically target and destroy cancer cells. By combining these platforms with cutting-edge technologies, Scancell is committed to advancing personalized medicine and improving patient outcomes in the field of oncology.

What is the P/E ratio of Scancell Holdings 2024?

The Scancell Holdings P/E ratio is -7.04.

What is the P/S ratio of Scancell Holdings 2024?

The Scancell Holdings P/S ratio is 0.

What is the Quality Investing of Scancell Holdings?

The Quality Investing for Scancell Holdings is 5/10.

What is the revenue of Scancell Holdings 2024?

The revenue cannot currently be calculated for Scancell Holdings.

How high is the profit of Scancell Holdings 2024?

The expected Scancell Holdings profit is -17.8 M GBP.

What is the business model of Scancell Holdings

Scancell Holdings PLC is a biopharmaceutical company based in the UK that specializes in the development of cancer therapies and vaccines. The company was founded in 1997 and has since become one of the leading companies in this field.

What is the Scancell Holdings dividend?

Scancell Holdings pays a dividend of 0 GBP distributed over payouts per year.

How often does Scancell Holdings pay dividends?

The dividend cannot currently be calculated for Scancell Holdings or the company does not pay out a dividend.

What is the Scancell Holdings ISIN?

The ISIN of Scancell Holdings is GB00B63D3314.

What is the Scancell Holdings WKN?

The WKN of Scancell Holdings is A1JZ3D.

What is the Scancell Holdings ticker?

The ticker of Scancell Holdings is SCLP.L.

How much dividend does Scancell Holdings pay?

Over the past 12 months, Scancell Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Scancell Holdings is expected to pay a dividend of 0 GBP.

What is the dividend yield of Scancell Holdings?

The current dividend yield of Scancell Holdings is .

When does Scancell Holdings pay dividends?

Scancell Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Scancell Holdings?

Scancell Holdings paid dividends every year for the past 0 years.

What is the dividend of Scancell Holdings?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Scancell Holdings located?

Scancell Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Scancell Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Scancell Holdings from 11/19/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Scancell Holdings pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Scancell Holdings in the year 2023?

In the year 2023, Scancell Holdings distributed 0 GBP as dividends.

In which currency does Scancell Holdings pay out the dividend?

The dividends of Scancell Holdings are distributed in GBP.

All fundamentals about Scancell Holdings

Our stock analysis for Scancell Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Scancell Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.